Back

광동제약 KOSPI

009290

Suggest a tag

Watch

Notes Naver Finance

Meeting voting results

Annual 2026.03.26

Participation 63.8% Minority 55.7% Max. opposition 17.5% DART

1 제53기 재무제표(이익잉여금처분계산서 포함) 및 연결재무제표 승인의 건 Approved Approval 99.1%
2-1 주주총회 개최방식 및 의결권 대리행사 방식에 대한 변경 Approved Approval 99.2%
2-2 독립이사 제도 반영을 위한 변경 Approved Approval 99.4%
2-3 감사위원회 위원 분리선임 인원 및 의결권제한 방식에 대한 변경 Approved Approval 99.4%
2-4 각자대표 체제 도입에 따른 변경 Approved Approval 99.3%
2-5 위원회 설립을 위한 변경 Approved Approval 99.3%
2-6 주주명부 폐쇄 조항 삭제를 위한 변경 Approved Approval 99.3%
2-7 기타 조문 정비를 위한 변경 Approved Approval 99.3%
3 사내이사 선임의 건(후보자 : 박상영) Approved Approval 82.5%
4 감사위원이 되는 사외이사 선임의 건(후보자 : 이재원) Approved Approval 98.7%
5 이사 보수 한도액 승인의 건 Approved Approval 92.4%

Previous meeting results

Financial indicators

Market cap

3,112 × 100M KRW

Approx. 3,106 × 100M KRW excluding treasury shares

PBR

0.49

PER

14.7

ROE

3.40%

Dividend yield

1.60%

Debt-to-equity ratio

85.5%

Share price history

Share price

Daily close

Latest close

5-year high

5-year low

Use the period buttons above to adjust the range.

Shareholder distribution

Based on 2026 Semiannual report (2026-06-30)

Controlling shareholders total

19.08%

Minority shareholders (excl. related parties)

39.82%

Large outside holders (1%+)

40.90% (25 people)

Treasury shares

0.20%

Total shareholders

37,684 people

Annual earnings Trend

Financial statements

Consolidated · includes subsidiaries

광동제약 — Annual Consolidated Financial statements
Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Income statement
Revenue	4,683.8 × 100M KRW	5,222.7 × 100M KRW	9,554.5 × 100M KRW	1.1T KRW	1.1T KRW	1.2T KRW	1.2T KRW	1.2T KRW	1.3T KRW	1.4T KRW	1.5T KRW	1.6T KRW	1.7T KRW
Operating profit	443.9 × 100M KRW	504.6 × 100M KRW	508.7 × 100M KRW	443.9 × 100M KRW	357.4 × 100M KRW	339.4 × 100M KRW	418 × 100M KRW	465.9 × 100M KRW	449.4 × 100M KRW	382.4 × 100M KRW	420.7 × 100M KRW	301 × 100M KRW	310.5 × 100M KRW
Net income	220 × 100M KRW	350.6 × 100M KRW	360.8 × 100M KRW	279 × 100M KRW	230.8 × 100M KRW	219.7 × 100M KRW	226.6 × 100M KRW	456 × 100M KRW	255.4 × 100M KRW	267 × 100M KRW	393.7 × 100M KRW	418.4 × 100M KRW	213.3 × 100M KRW
Operating margin	9.48%	9.66%	5.32%	4.20%	3.13%	2.88%	3.38%	3.75%	3.36%	2.67%	2.78%	1.83%	1.87%
Balance sheet
Total assets	4,256.8 × 100M KRW	4,425.3 × 100M KRW	6,637.9 × 100M KRW	6,797.8 × 100M KRW	7,227 × 100M KRW	7,320.6 × 100M KRW	7,927.8 × 100M KRW	8,306.4 × 100M KRW	8,838.5 × 100M KRW	9,320.2 × 100M KRW	1.1T KRW	1.2T KRW	1.3T KRW
Total liabilities	1,348.5 × 100M KRW	1,281.3 × 100M KRW	2,860.6 × 100M KRW	2,801 × 100M KRW	3,064 × 100M KRW	3,012.2 × 100M KRW	3,453.2 × 100M KRW	3,284.6 × 100M KRW	3,566 × 100M KRW	3,849.8 × 100M KRW	4,900.2 × 100M KRW	5,520.1 × 100M KRW	6,085.3 × 100M KRW
Total equity	2,908.2 × 100M KRW	3,144 × 100M KRW	3,777.3 × 100M KRW	3,996.8 × 100M KRW	4,163 × 100M KRW	4,308.4 × 100M KRW	4,474.6 × 100M KRW	5,021.8 × 100M KRW	5,272.4 × 100M KRW	5,470.5 × 100M KRW	5,880.5 × 100M KRW	6,182.7 × 100M KRW	7,118 × 100M KRW
Cash flow statement
Operating cash flow	-	-	-	-	-	-	-	-	-	-	-	-121.5 × 100M KRW	823.4 × 100M KRW
Investing cash flow	-	-	-	-	-	-	-	-	-	-	-	127.7 × 100M KRW	-1,025.8 × 100M KRW
Financing cash flow	-	-	-	-	-	-	-	-	-	-	-	367.6 × 100M KRW	455.2 × 100M KRW
Investment indicators
ROE	7.56%	11.15%	9.55%	6.98%	5.54%	5.10%	5.06%	9.08%	4.84%	4.88%	6.70%	6.77%	3.00%
Debt-to-equity ratio	46.37%	40.76%	75.73%	70.08%	73.60%	69.91%	77.17%	65.41%	67.63%	70.37%	83.33%	89.28%	85.49%
Separate total assets	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-
PER	-	-	-	-	-	-	-	-	-	-	-	-	-
PBR	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividend per share	KRW 70	KRW 80	KRW 80	KRW 80	KRW 80	KRW 80	KRW 80	KRW 100	KRW 100	KRW 100	KRW 100	KRW 100	KRW 100
Detailed accounts
Current assets	-	-	3,966.3 × 100M KRW	-	-	4,590.8 × 100M KRW	-	-	5,878.2 × 100M KRW	-	-	7,191.1 × 100M KRW	7,176.3 × 100M KRW
Non-current assets	-	-	2,671.5 × 100M KRW	-	-	2,729.7 × 100M KRW	-	-	2,960.3 × 100M KRW	-	-	4,511.6 × 100M KRW	6,027 × 100M KRW
Current liabilities	-	-	2,230 × 100M KRW	-	-	2,713.5 × 100M KRW	-	-	3,255 × 100M KRW	-	-	4,613 × 100M KRW	5,259.2 × 100M KRW
Non-current liabilities	-	-	630.6 × 100M KRW	-	-	298.6 × 100M KRW	-	-	311.1 × 100M KRW	-	-	907.1 × 100M KRW	826.1 × 100M KRW
Equity attributable to owners	-	-	-	-	-	-	-	-	-	-	-	5,791.2 × 100M KRW	6,555.8 × 100M KRW
Share capital	-	-	-	-	-	524.2 × 100M KRW	-	-	524.2 × 100M KRW	-	-	524.2 × 100M KRW	524.2 × 100M KRW
Capital surplus	-	-	-	-	-	-	-	-	-	-	-	581.7 × 100M KRW	708 × 100M KRW
Accumulated other comprehensive income	-	-	-	-	-	-	-	-	-	-	-	45.5 × 100M KRW	24.7 × 100M KRW
Retained earnings	-	-	2,865.7 × 100M KRW	-	-	3,495.5 × 100M KRW	-	-	4,332.2 × 100M KRW	-	-	5,209.1 × 100M KRW	5,401.3 × 100M KRW
Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	391.5 × 100M KRW	562.2 × 100M KRW

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

광동제약 — Quarterly Consolidated Financial statements
Item	24/3	24/6	24/9	24/12	25/3	25/6	25/9	25/12	26/3	26/6
Income statement
Revenue	4,124.9 × 100M KRW	4,128.1 × 100M KRW	4,245.9 × 100M KRW	3,908.3 × 100M KRW	3,776 × 100M KRW	4,252.9 × 100M KRW	4,445.2 × 100M KRW	4,121 × 100M KRW	4,108.5 × 100M KRW	4,398.2 × 100M KRW
Operating profit	170.3 × 100M KRW	50.4 × 100M KRW	13.7 × 100M KRW	66.5 × 100M KRW	33.1 × 100M KRW	45.4 × 100M KRW	108.7 × 100M KRW	123.3 × 100M KRW	75.2 × 100M KRW	28.2 × 100M KRW
Net income	183.6 × 100M KRW	17 × 100M KRW	89.5 × 100M KRW	128.3 × 100M KRW	-	-	-	-	-	-
Operating margin	4.13%	1.22%	0.32%	1.70%	0.88%	1.07%	2.45%	2.99%	1.83%	0.64%
Balance sheet
Total assets	1.1T KRW	1.1T KRW	1.2T KRW	1.2T KRW	1.2T KRW	1.2T KRW	1.2T KRW	1.3T KRW	1.3T KRW	1.3T KRW
Total liabilities	5,013 × 100M KRW	5,301.5 × 100M KRW	5,655.8 × 100M KRW	5,520.1 × 100M KRW	5,454.9 × 100M KRW	5,599.9 × 100M KRW	5,899 × 100M KRW	6,085.3 × 100M KRW	6,060.9 × 100M KRW	6,054 × 100M KRW
Total equity	6,051.2 × 100M KRW	6,054.5 × 100M KRW	6,166.7 × 100M KRW	6,182.7 × 100M KRW	6,167.2 × 100M KRW	6,200 × 100M KRW	6,322 × 100M KRW	7,118 × 100M KRW	7,123.1 × 100M KRW	7,050.1 × 100M KRW
Cash flow statement
Operating cash flow	-209.2 × 100M KRW	-101.1 × 100M KRW	286.1 × 100M KRW	-97.3 × 100M KRW	193.6 × 100M KRW	217.9 × 100M KRW	260.3 × 100M KRW	151.6 × 100M KRW	-107.5 × 100M KRW	-127.5 × 100M KRW
Investing cash flow	87.4 × 100M KRW	-172.1 × 100M KRW	186.6 × 100M KRW	25.8 × 100M KRW	81.8 × 100M KRW	-605.6 × 100M KRW	2.4 × 100M KRW	-504.4 × 100M KRW	-310.6 × 100M KRW	117.2 × 100M KRW
Financing cash flow	139.5 × 100M KRW	207 × 100M KRW	144.4 × 100M KRW	-123.2 × 100M KRW	-26.7 × 100M KRW	-56 × 100M KRW	-54.7 × 100M KRW	592.5 × 100M KRW	-34.8 × 100M KRW	-81.1 × 100M KRW
Investment indicators
Debt-to-equity ratio	82.84%	87.56%	91.72%	89.28%	88.45%	90.32%	93.31%	85.49%	85.09%	85.87%
EPS	KRW 454	KRW 33	KRW 220	-	-	-	-	-	-	-
Detailed accounts
Current assets	6,867.9 × 100M KRW	6,683 × 100M KRW	7,184.1 × 100M KRW	7,191.1 × 100M KRW	7,015.2 × 100M KRW	7,132.9 × 100M KRW	7,054.2 × 100M KRW	7,176.3 × 100M KRW	6,852.5 × 100M KRW	7,027.3 × 100M KRW
Non-current assets	4,196.3 × 100M KRW	4,673 × 100M KRW	4,638.3 × 100M KRW	4,511.6 × 100M KRW	4,607 × 100M KRW	4,667 × 100M KRW	5,166.7 × 100M KRW	6,027 × 100M KRW	6,331.6 × 100M KRW	6,076.7 × 100M KRW
Current liabilities	4,667.2 × 100M KRW	4,833.6 × 100M KRW	5,104.5 × 100M KRW	4,613 × 100M KRW	4,547.2 × 100M KRW	4,658 × 100M KRW	4,991.7 × 100M KRW	5,259.2 × 100M KRW	5,273.9 × 100M KRW	5,241.5 × 100M KRW
Non-current liabilities	345.9 × 100M KRW	467.9 × 100M KRW	551.3 × 100M KRW	907.1 × 100M KRW	907.8 × 100M KRW	941.9 × 100M KRW	907.2 × 100M KRW	826.1 × 100M KRW	787 × 100M KRW	812.4 × 100M KRW
Equity attributable to owners	5,612.4 × 100M KRW	5,623.4 × 100M KRW	5,736.3 × 100M KRW	5,791.2 × 100M KRW	5,772.4 × 100M KRW	5,809.9 × 100M KRW	5,925.3 × 100M KRW	6,555.8 × 100M KRW	6,466.1 × 100M KRW	6,386.7 × 100M KRW
Share capital	524.2 × 100M KRW	524.2 × 100M KRW	524.2 × 100M KRW	524.2 × 100M KRW	524.2 × 100M KRW	524.2 × 100M KRW	524.2 × 100M KRW	524.2 × 100M KRW	524.2 × 100M KRW	524.2 × 100M KRW
Capital surplus	553.2 × 100M KRW	553.2 × 100M KRW	553.5 × 100M KRW	581.7 × 100M KRW	581.9 × 100M KRW	581.9 × 100M KRW	581.9 × 100M KRW	708 × 100M KRW	709.3 × 100M KRW	709.3 × 100M KRW
Accumulated other comprehensive income	69.6 × 100M KRW	67.1 × 100M KRW	91.9 × 100M KRW	45.5 × 100M KRW	11.9 × 100M KRW	24.3 × 100M KRW	31.3 × 100M KRW	24.7 × 100M KRW	-27 × 100M KRW	-134.6 × 100M KRW
Retained earnings	4,993.2 × 100M KRW	5,006.7 × 100M KRW	5,094.9 × 100M KRW	5,209.1 × 100M KRW	5,227.3 × 100M KRW	5,252.3 × 100M KRW	5,360.2 × 100M KRW	5,401.3 × 100M KRW	5,262.5 × 100M KRW	5,289 × 100M KRW
Non-controlling interests	438.7 × 100M KRW	431.1 × 100M KRW	430.3 × 100M KRW	391.5 × 100M KRW	394.7 × 100M KRW	390.1 × 100M KRW	396.7 × 100M KRW	562.2 × 100M KRW	657.1 × 100M KRW	663.3 × 100M KRW

Income figures cover the quarter, not the year to date. Balance sheet figures are quarter-end balances.

Quarterly cash flow is calculated from changes in cumulative totals.

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

Separate · this company only

광동제약 — Annual Separate Financial statements
Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Income statement
Revenue	4,674.2 × 100M KRW	5,209.7 × 100M KRW	5,722.6 × 100M KRW	6,363.2 × 100M KRW	6,885.4 × 100M KRW	6,970.8 × 100M KRW	7,488.9 × 100M KRW	7,643.1 × 100M KRW	8,252.3 × 100M KRW	8,505.3 × 100M KRW	9,170.7 × 100M KRW	9,748.4 × 100M KRW	1T KRW
Operating profit	442.7 × 100M KRW	504.6 × 100M KRW	486.6 × 100M KRW	457.2 × 100M KRW	368.7 × 100M KRW	337.5 × 100M KRW	412.6 × 100M KRW	448.4 × 100M KRW	415.8 × 100M KRW	335.7 × 100M KRW	397.4 × 100M KRW	281.3 × 100M KRW	305.9 × 100M KRW
Net income	214.4 × 100M KRW	344.8 × 100M KRW	333.6 × 100M KRW	291.7 × 100M KRW	238.5 × 100M KRW	229.9 × 100M KRW	229.2 × 100M KRW	303 × 100M KRW	304.2 × 100M KRW	237.4 × 100M KRW	319.9 × 100M KRW	249.8 × 100M KRW	222.7 × 100M KRW
Operating margin	9.47%	9.69%	8.50%	7.19%	5.35%	4.84%	5.51%	5.87%	5.04%	3.95%	4.33%	2.89%	3.03%
Balance sheet
Total assets	4,167.9 × 100M KRW	4,319.5 × 100M KRW	5,116.1 × 100M KRW	5,456 × 100M KRW	5,841 × 100M KRW	5,891.6 × 100M KRW	6,560.4 × 100M KRW	6,828.4 × 100M KRW	7,169.2 × 100M KRW	7,676.3 × 100M KRW	8,553.2 × 100M KRW	9,323.9 × 100M KRW	1T KRW
Total liabilities	1,320.8 × 100M KRW	1,245.7 × 100M KRW	1,690 × 100M KRW	1,790.4 × 100M KRW	1,993.5 × 100M KRW	1,903.9 × 100M KRW	2,350.6 × 100M KRW	2,217.5 × 100M KRW	2,311.5 × 100M KRW	2,616.4 × 100M KRW	3,295.4 × 100M KRW	3,904.4 × 100M KRW	4,089.1 × 100M KRW
Total equity	2,847 × 100M KRW	3,073.7 × 100M KRW	3,426.1 × 100M KRW	3,665.6 × 100M KRW	3,847.5 × 100M KRW	3,987.7 × 100M KRW	4,209.8 × 100M KRW	4,610.9 × 100M KRW	4,857.6 × 100M KRW	5,059.9 × 100M KRW	5,257.7 × 100M KRW	5,419.5 × 100M KRW	6,138.2 × 100M KRW
Cash flow statement
Operating cash flow	-	-	-	-	-	-	-	-	-	-	-	-274.1 × 100M KRW	726.2 × 100M KRW
Investing cash flow	-	-	-	-	-	-	-	-	-	-	-	89.7 × 100M KRW	-1,171 × 100M KRW
Financing cash flow	-	-	-	-	-	-	-	-	-	-	-	404.8 × 100M KRW	534.7 × 100M KRW
Investment indicators
ROE	7.53%	11.22%	9.74%	7.96%	6.20%	5.77%	5.45%	6.57%	6.26%	4.69%	6.08%	4.61%	3.63%
Debt-to-equity ratio	46.39%	40.53%	49.33%	48.84%	51.81%	47.75%	55.84%	48.09%	47.59%	51.71%	62.68%	72.04%	66.62%
Separate total assets	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-
PER	-	-	-	-	-	-	-	-	-	-	-	-	-
PBR	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividend per share	KRW 70	KRW 80	KRW 80	KRW 80	KRW 80	KRW 80	KRW 80	KRW 100	KRW 100	KRW 100	KRW 100	KRW 100	KRW 100
Detailed accounts
Current assets	-	-	2,318.7 × 100M KRW	-	-	2,938.4 × 100M KRW	-	-	3,859.8 × 100M KRW	-	-	4,786.7 × 100M KRW	4,369.3 × 100M KRW
Non-current assets	-	-	2,797.4 × 100M KRW	-	-	2,953.2 × 100M KRW	-	-	3,309.4 × 100M KRW	-	-	4,537.2 × 100M KRW	5,858 × 100M KRW
Current liabilities	-	-	1,117.8 × 100M KRW	-	-	1,637.8 × 100M KRW	-	-	2,035.7 × 100M KRW	-	-	3,236.9 × 100M KRW	3,514.7 × 100M KRW
Non-current liabilities	-	-	572.2 × 100M KRW	-	-	266.1 × 100M KRW	-	-	275.9 × 100M KRW	-	-	667.5 × 100M KRW	574.3 × 100M KRW
Share capital	-	-	-	-	-	524.2 × 100M KRW	-	-	524.2 × 100M KRW	-	-	524.2 × 100M KRW	524.2 × 100M KRW
Capital surplus	-	-	-	-	-	-	-	-	-	-	-	572.2 × 100M KRW	696.4 × 100M KRW
Accumulated other comprehensive income	-	-	-	-	-	-	-	-	-	-	-	27.3 × 100M KRW	-14.7 × 100M KRW
Retained earnings	-	-	2,798.6 × 100M KRW	-	-	3,454.4 × 100M KRW	-	-	4,191.3 × 100M KRW	-	-	4,864.8 × 100M KRW	5,049.4 × 100M KRW

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

광동제약 — Quarterly Separate Financial statements
Item	24/3	24/6	24/9	24/12	25/3	25/6	25/9	25/12	26/3	26/6
Income statement
Revenue	-	-	-	-	-	-	-	-	2,370.4 × 100M KRW	-
Operating profit	-	-	-	-	-	-	-	-	61.9 × 100M KRW	-
Net income	-	-	-	-	-	-	-	-	-	-
Operating margin	-	-	-	-	-	-	-	-	2.61%	-
Balance sheet
Total assets	-	-	-	-	-	-	-	-	1T KRW	-
Total liabilities	-	-	-	-	-	-	-	-	4,155 × 100M KRW	-
Total equity	-	-	-	-	-	-	-	-	6,072.4 × 100M KRW	-
Cash flow statement
Operating cash flow	-	-	-	-	-	-	-	-	-75.7 × 100M KRW	-
Investing cash flow	-	-	-	-	-	-	-	-	-144.9 × 100M KRW	-
Financing cash flow	-	-	-	-	-	-	-	-	-7,285 × 10,000 KRW	-
Investment indicators
Debt-to-equity ratio	-	-	-	-	-	-	-	-	68.42%	-
EPS	-	-	-	-	-	-	-	-	-	-
Detailed accounts
Current assets	-	-	-	4,786.7 × 100M KRW	-	-	-	4,369.3 × 100M KRW	4,257.2 × 100M KRW	-
Non-current assets	-	-	-	4,537.2 × 100M KRW	-	-	-	5,858 × 100M KRW	5,970.1 × 100M KRW	-
Current liabilities	-	-	-	3,236.9 × 100M KRW	-	-	-	3,514.7 × 100M KRW	3,606.5 × 100M KRW	-
Non-current liabilities	-	-	-	667.5 × 100M KRW	-	-	-	574.3 × 100M KRW	548.5 × 100M KRW	-
Share capital	-	-	-	524.2 × 100M KRW	-	-	-	524.2 × 100M KRW	524.2 × 100M KRW	-
Capital surplus	-	-	-	572.2 × 100M KRW	-	-	-	696.4 × 100M KRW	696.4 × 100M KRW	-
Accumulated other comprehensive income	-	-	-	27.3 × 100M KRW	-	-	-	-14.7 × 100M KRW	-71.7 × 100M KRW	-
Retained earnings	-	-	-	4,864.8 × 100M KRW	-	-	-	5,049.4 × 100M KRW	4,923.7 × 100M KRW	-

Income figures cover the quarter, not the year to date. Balance sheet figures are quarter-end balances.

Quarterly cash flow is calculated from changes in cumulative totals.

ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.

Legacy summaries and estimates; may include data with unverified accounting scope.

광동제약 — Annual Legacy summary & estimates Financial statements
Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023 Consolidated	2024 Consolidated	2025 Consolidated
Income statement
Revenue	4,683.8 × 100M KRW	5,222.7 × 100M KRW	9,554.5 × 100M KRW	1.1T KRW	1.1T KRW	1.2T KRW	1.2T KRW	1.2T KRW	1.3T KRW	1.4T KRW	1.5T KRW	1.6T KRW	1.7T KRW
Operating profit	443.9 × 100M KRW	504.6 × 100M KRW	508.7 × 100M KRW	443.9 × 100M KRW	357.4 × 100M KRW	339.4 × 100M KRW	418 × 100M KRW	465.9 × 100M KRW	449.4 × 100M KRW	382.4 × 100M KRW	420.7 × 100M KRW	301 × 100M KRW	310.5 × 100M KRW
Net income	220 × 100M KRW	350.6 × 100M KRW	360.8 × 100M KRW	279 × 100M KRW	230.8 × 100M KRW	219.7 × 100M KRW	226.6 × 100M KRW	456 × 100M KRW	255.4 × 100M KRW	267 × 100M KRW	393.7 × 100M KRW	418.4 × 100M KRW	213.3 × 100M KRW
Operating margin	9.48%	9.66%	5.32%	4.20%	3.13%	2.88%	3.38%	3.75%	3.36%	2.67%	2.78%	1.83%	1.87%
Balance sheet
Total assets	-	-	-	-	-	-	-	-	-	-	1.1T KRW	1.2T KRW	1.3T KRW
Total liabilities	1,348.5 × 100M KRW	1,281.3 × 100M KRW	2,860.6 × 100M KRW	2,801 × 100M KRW	3,064 × 100M KRW	3,012.2 × 100M KRW	3,453.2 × 100M KRW	3,284.6 × 100M KRW	3,566 × 100M KRW	3,849.8 × 100M KRW	4,900.2 × 100M KRW	5,520.1 × 100M KRW	6,085.3 × 100M KRW
Total equity	2,908.2 × 100M KRW	3,144 × 100M KRW	3,777.3 × 100M KRW	3,996.8 × 100M KRW	4,163 × 100M KRW	4,308.4 × 100M KRW	4,474.6 × 100M KRW	5,021.8 × 100M KRW	5,272.4 × 100M KRW	5,470.5 × 100M KRW	5,880.5 × 100M KRW	6,182.7 × 100M KRW	7,118 × 100M KRW
Investment indicators
ROE	7.56%	11.15%	9.55%	6.98%	5.54%	5.10%	5.06%	9.08%	4.84%	4.88%	6.70%	6.77%	3.00%
Debt-to-equity ratio	46.37%	40.76%	75.73%	70.08%	73.60%	69.91%	77.17%	65.41%	67.63%	70.37%	83.33%	89.28%	85.49%
Separate total assets	-	-	-	-	-	-	-	-	-	-	8,553.2 × 100M KRW	9,323.9 × 100M KRW	1T KRW
EPS	-	-	-	KRW 692	KRW 572	KRW 551	KRW 582	KRW 1,119	KRW 585	KRW 461	KRW 705	KRW 772	KRW 400
PER	-	-	-	-	-	-	-	-	-	12.92×	10.54×	7.04×	14.65×
PBR	-	-	-	-	-	-	-	-	-	0.47	0.55	0.37	0.44
Dividend per share	KRW 70	KRW 80	KRW 80	KRW 80	KRW 80	KRW 80	KRW 80	KRW 100	KRW 100	KRW 100	KRW 100	KRW 100	KRW 100

광동제약 — Quarterly Legacy summary & estimates Financial statements
Item	24/3 Consolidated	24/6 Consolidated	24/9 Consolidated	24/12 Consolidated	25/3 Consolidated	25/6 Consolidated	25/9 Consolidated	25/12 Consolidated	26/3 Consolidated	26/6 Consolidated
Income statement
Revenue	4,124.9 × 100M KRW	4,128.1 × 100M KRW	4,245.9 × 100M KRW	3,908.3 × 100M KRW	3,776 × 100M KRW	4,252.9 × 100M KRW	4,445.2 × 100M KRW	4,121 × 100M KRW	4,108.5 × 100M KRW	4,398.2 × 100M KRW
Operating profit	170.3 × 100M KRW	50.4 × 100M KRW	13.7 × 100M KRW	66.5 × 100M KRW	33.1 × 100M KRW	45.4 × 100M KRW	108.7 × 100M KRW	123.3 × 100M KRW	75.2 × 100M KRW	28.2 × 100M KRW
Net income	183.6 × 100M KRW	17 × 100M KRW	89.5 × 100M KRW	128.3 × 100M KRW	-	-	-	-	-	-
Operating margin	4.13%	1.22%	0.32%	1.70%	0.88%	1.07%	2.45%	2.99%	1.83%	0.64%
Balance sheet
Total assets	1.1T KRW	1.1T KRW	1.2T KRW	1.2T KRW	1.2T KRW	1.2T KRW	1.2T KRW	1.3T KRW	1.3T KRW	1.3T KRW
Total liabilities	5,013 × 100M KRW	5,301.5 × 100M KRW	5,655.8 × 100M KRW	5,520.1 × 100M KRW	5,454.9 × 100M KRW	5,599.9 × 100M KRW	5,899 × 100M KRW	6,085.3 × 100M KRW	6,060.9 × 100M KRW	6,054 × 100M KRW
Total equity	6,051.2 × 100M KRW	6,054.5 × 100M KRW	6,166.7 × 100M KRW	6,182.7 × 100M KRW	6,167.2 × 100M KRW	6,200 × 100M KRW	6,322 × 100M KRW	7,118 × 100M KRW	7,123.1 × 100M KRW	7,050.1 × 100M KRW
Investment indicators
Debt-to-equity ratio	82.84%	87.56%	91.72%	89.28%	88.45%	90.32%	93.31%	85.49%	85.09%	85.87%
EPS	KRW 454	KRW 33	KRW 220	-	-	-	-	-	-	-

Income figures cover the quarter, not the year to date. Balance sheet figures are quarter-end balances.

Property holdings

Total book value

2,149 × 100M KRW

Total assessed land value

1,170 × 100M KRW

Ratio to market cap

69.0%

Land

4 records

Buildings

4 records

Category	Location	Use	Area	Book value	Assessed land value
Building Unverified	갈현동	업무용	23,373m²	651 × 100M KRW	-
투자부동산 Unverified	서초동및 안양	임대용 토지	7,904m²	364 × 100M KRW	516 × 100M KRW
Building Unverified	장당동	공장용	36,754m²	293 × 100M KRW	-
Land Unverified	갈현동	업무용	2,396m²	199 × 100M KRW	89 × 100M KRW
Building Unverified	안양 外	-	10,364m²	140 × 100M KRW	-
투자부동산 Unverified	서초동및 안양	임대용 건물	15,330m²	118 × 100M KRW	98 × 100M KRW
Land Unverified	안양 外	-	8,375m²	109 × 100M KRW	81 × 100M KRW
Building Unverified	모곡동	공장용	13,843m²	108 × 100M KRW	-
Land Unverified	장당동	공장용지	50,636m²	88 × 100M KRW	317 × 100M KRW
기타 Unverified	모곡동外	구축물	-	58 × 100M KRW	-
Land Unverified	모곡동	공장용지	9,801m²	17 × 100M KRW	66 × 100M KRW
투자부동산 Unverified	서초동및 안양	임대용 구축물	-	3 × 100M KRW	3 × 100M KRW

Ownership structure

Listed subsidiary stake value 515 × 100M KRW (Sum of market cap × ownership)

Is a listed company shown as unlisted?

Corporate shareholders

Corporate and institutional holders identified in collected disclosures. This is not a complete shareholder register. Reporting-group holdings may overlap with individual holdings.

Business report analysis

Analysis date 2026.05.25 23:46 | Based on 2025 Annual report

Unverified Original business report

사업 개요

광동제약은 의약품 제조 및 판매, 의약부외품, 식품 제조·판매, 약국·병원·F&B 영업을 영위하는 제약 및 식음료 기업입니다.
2025년 연결기준 매출액은 약 1조 6,595억원, 종속회사를 제외한 개별기준 매출액은 약 1조 110억원입니다.

주요 매출원

표 기준 총 제품·상품 판매실적은 약 1조 110억원이며, 내수 약 9,971억원(98.6%), 수출 약 139억원(1.4%)입니다.
F&B영업: 약 4,727억원(46.8%). 제주삼다수 약 3,183억원(31.5%), 비타500류 약 819억원(8.1%), 옥수수수염차 약 367억원(3.6%), 헛개차 약 358억원(3.5%)입니다.
기타 제품·상품: 약 2,419억원(23.9%). 내수 약 2,280억원, 수출 약 139억원입니다.
병원영업: 약 1,824억원(18.0%). 가다실 약 1,174억원(11.6%), 싱그릭스 약 225억원(2.2%), 레나라 약 133억원(1.3%)입니다.
약국영업: 약 1,140억원(11.3%). 청심원류 약 559억원(5.5%), 쌍화탕류 약 256억원(2.5%), 비타500류 약 181억원(1.8%), 경옥고류 약 144억원(1.4%)입니다.

원가 구조 / 비용 특성

제53기 매출원가는 약 7,424억원으로 매출액 대비 약 73.4%입니다. 전기 매출원가율 약 72.6%, 전전기 약 70.4% 대비 상승했습니다.
제53기 판매비와 관리비는 약 2,380억원, 영업이익은 약 306억원으로 영업이익률은 약 3.0%입니다. 영업이익은 전기 약 281억원보다 증가했지만 전전기 약 397억원보다는 낮습니다.

자회사

영업보고서 자회사 현황에는 13개 자회사가 기재되어 있습니다.
주요 자회사는 코리아e플랫폼(도매업), KD인베스트먼트(금융서비스), 가산(제조·도소매), 광동헬스바이오(기타 식료품 제조업), 프리시젼바이오(의료용품 제조업)입니다.

차입 구조

주요채권자는 산업은행 약 1,480억원, 우리은행 약 380억원, 수출입은행 약 296억원, 신한은행 약 200억원, 농협은행 약 100억원, 하나은행 약 40억원이며, 합계 약 2,496억원입니다.

Employees

1,022 people

Subsidiaries

13 items

Material subsequent events

주주가치 제고를 위해 2025년 12월 23일 이사회 결의로 배당가능이익 내 취득한 자기주식 2,621,043주의 소각을 결정했습니다. 소각효력일은 2026년 1월 9일이며 보고서 제출일 현재 소각 완료되었습니다.

Articles of incorporation analysis

Analysis date 2026.06.20 01:25 | Last amended 2024.03.26

Unverified Original articles of incorporation

주주친화

동등배당: 배당기준일 현재 발행 또는 전환된 동종주식에 대해 발행일과 관계없이 모두 동등하게 배당 (제9조의4)
감사위원 분리선임: 감사위원 중 1명 이상은 다른 이사들과 분리하여 선임 (제40조의2④)
중간배당: 이사회 결의로 중간배당을 할 수 있음 (제44조의2)

주주비친화

집중투표제 명시적 배제: 2인 이상 이사를 선임하는 경우에도 상법 제382조의2의 집중투표제를 적용하지 않아 소수주주 이사 선임 가능성을 낮춤 (제29조③)
이사 임기 3년 고정: 이사 임기를 상법상 최장 수준인 3년으로 고정 (제30조)
이사회 결의만으로 1,000억원 전환사채 제3자 배정: 경영상 목적 등을 이유로 주주 외의 자에게 전환사채를 발행할 수 있어 경영권 분쟁 시 우호지분 확보 수단이 될 수 있음 (제14조①)
이사회 결의만으로 500억원 신주인수권부사채 제3자 배정: 주주 외의 자에게 신주인수권부사채를 발행할 수 있어 기존 주주 지분 희석 위험이 있음 (제15조①)
이사 책임감경 조항: 최근 1년 보수액의 6배, 사외이사는 3배 초과분에 대해 책임 면제가 가능해 주주대표소송의 실효성을 약화시킬 수 있음 (제37조의2)

기타 주목 조항

감사위원회 체제: 감사에 갈음하여 3인 이상의 이사로 구성되는 감사위원회를 두며, 위원의 3분의 2 이상은 사외이사여야 함 (제40조의2)
대표이사 이사회 의장 겸임: 대표이사가 이사회 의장이 됨 (제33조①)

Board of directors

Number of directors

3–6 people

Director term

3 years (Fixed)

Staggered board

None

Cumulative voting

Separate chair and CEO

Gender diversity requirement

Director liability limitation

Exemption above 6.0×

Auditors

Number of auditors

At least 3 people

Auditor term

Shareholder meetings and dividends

Meeting notice period

14 days

Written voting

Electronic voting

Dividend record date

Third-party allotment limit by board resolution alone

Convertible bonds (CB)

1,000 × 100M KRW

Bonds with warrants (BW)

500 × 100M KRW

Compensation basis

Director: 이사의 보수는 주주총회의 결의로 정한다.
Retirement payments: 이사의 퇴직금은 주주총회 결의를 거친 임원퇴직금 지급규정에 의한다.

Executive compensation

Based on 2025 Annual report

Total compensation

19 × 100M KRW

Executives

6 people

Average per executive

3 × 100M KRW

Total dividends

50 × 100M KRW

Compensation / dividends

0.4×

Controlling shareholders

Name	Relationship	Age	Ownership
최성원	Self	-	6.59%
가산문화재단	기타	-	5.00%
광동생활건강	기타	-	3.51%
박일희	친인척	-	1.29%
손현주	친인척	-	0.48%
최윤석	친인척	-	0.48%
이강남	친인척	-	0.38%
모과균	계열사임원	-	0.11%
최지선	친인척	-	0.11%
이혁종	계열사임원	-	0.10%
최지원	친인척	-	0.10%
최행선	친인척	-	0.04%
박상영	Registered executive	-	0.01%
이채주	Registered executive	-	0.01%
설상현	계열사임원	-	0.01%
이강주	계열사임원	-	0.00%

Holders of 5% or more

Holder	Holding ratio	Shares held	Change in ownership	Reason for filing	Report type	Filing date
최성원	19.11%	9,514,962	0.00%	보유주식 등에 관한 계약 연장	일반	2026-07-22
최성원	19.11%	9,514,962	0.00%	보유주식 등에 관한 계약 연장	일반	2026-06-30
최성원	19.11%	9,514,962	0.00%	보유주식 등에 관한 계약 연장	일반	2026-04-14
최성원	19.11%	9,514,962	+0.74%	1. 계열회사 임원 사임 2. 주식매수선택권 행사에 따른 보유형태 변경 및 주식수 변동	일반	2026-03-09
최성원	18.37%	9,630,915	0.00%	보유주식 등에 관한 계약 연장	일반	2025-12-31
최성원	18.37%	9,630,915	0.00%	보유주식 등에 관한 계약 연장	일반	2025-10-14
최성원	18.37%	9,630,915	0.00%	보유주식 등에 관한 계약 연장	일반	2025-09-25
최성원	18.37%	9,630,915	0.00%	보유주식 등에 관한 계약 연장	일반	2025-07-25
최성원	18.37%	9,630,915	0.00%	보유주식 등에 관한 계약 연장	일반	2025-06-26
최성원	18.37%	9,630,915	0.00%	보유주식 등에 관한 계약 해지	일반	2025-05-09
최성원	18.37%	9,630,915	+0.25%	장내 매수 / 보유주식 등에 관한 계약 연장	일반	2025-04-08
피델리티매니지먼트앤리서치컴퍼니엘엘씨	9.99%	5,236,834	+0.03%	운용펀드 추가에 의한 변동보고 운용펀드 해소에 의한 변동보고	약식	2025-02-19
최성원	18.12%	9,500,915	+0.03%	신규 계열회사 임원 선임	일반	2025-01-17
최성원	18.09%	9,481,680	0.00%	보유주식 등에 관한 계약 연장	일반	2024-12-27
최성원	18.09%	9,481,680	+0.10%	신규 계열회사 임원 선임 / 보유주식 등에 관한 계약 연장	일반	2024-10-08
최성원	17.99%	9,431,680	0.00%	보유주식 등에 관한 계약 연장	일반	2024-07-26
최성원	17.99%	9,431,680	0.00%	보유주식 등에 관한 계약 연장	일반	2024-06-28
최성원	17.99%	9,431,680	-0.04%	보유주식 등에 관한 계약 연장 / 계열회사 임원 사임	일반	2024-04-11

Auditors

Analysis date 2026.08.25 12:35

Auditor	Type	Term start	Term end	Tenure	D-day
이상원	Audit committee member	-	2025.03.25	5 years	Expired
염신일	Audit committee member	-	2026.03.24	5 years	Expired
강대희	Audit committee member	-	2027.03.26	5 years	D-141
강대희	Auditor	-	2027.03.26	5 years	D-141
정은진	Audit committee member	-	2028.03.26	1 years	D-507
정은진	Auditor	-	2028.03.26	1 years	D-507
이재원	Audit committee member	-	2029.03.26	1 years	D-872
이재원	Auditor	-	2029.03.26	1 years	D-872

Executives

Name	Position	Category	Age	Term end
박일희	명예부회장	미등기	Age 84	-
강대희	이사	독립이사	Age 64	D-141
박상영	대표이사 사장	Inside director	Age 63	D-872
정병기	상무	미등기	Age 60	-
박원호	전무	미등기	Age 60	-
최성원	대표이사 회장	Inside director	Age 57	D-507
양용만	상무	미등기	Age 57	-
구준모	상무	미등기	Age 56	-
이강주	상무	미등기	Age 56	-
정은진	이사	독립이사	Age 56	D-507
최환원	전무	미등기	Age 55	-
이상일	상무	미등기	Age 54	-
이채주	전무	Inside director	Age 54	D-141
한양수	상무	미등기	Age 53	-
이재원	이사	독립이사	Age 53	D-872
설상현	상무	미등기	Age 52	-
구본웅	상무	미등기	Age 52	-
박희범	상무	미등기	Age 52	-
박일범	상무	미등기	Age 51	-
이승재	상무	미등기	Age 50	-
안병일	상무	미등기	Age 50	-
정대석	상무	미등기	Age 50	-
배기룡	전무	미등기	Age 49	-
이후성	상무	미등기	Age 47	-

DART disclosures

Loading disclosures…

Activism & governance

Shareholder returns Importance 2 2026.11.04 20:00

광동제약의 저PBR과 자사주 처분·기업가치 제고 계획

기사는 광동제약의 저PBR과 수익성 지표를 다루며, 회사가 기업가치 제고 계획을 공시하지 않았다고 전했다. 자사주 처분 시점과 자사주 소각 의무화 법안의 발의·통과 시점도 언급했다.

Shareholder perspective 기업가치 제고 계획과 자사주 정책은 주주환원 및 자본배분과 관련된다. 다만 기사 요약은 구체적인 새 주주환원 결정이 아닌 현황 분석에 초점을 둔다.

광동제약 KOSPI

Meeting voting results Collapse Meeting voting results

Financial indicators Collapse Financial indicators

Share price history 10 years 5 years 3 years 1 year 3 months 1 week Collapse Share price history

Shareholder distribution Collapse Shareholder distribution

Annual earnings Trend Collapse Annual earnings

Financial statements Collapse Financial statements

Consolidated

Separate

Legacy summary & estimates

Property holdings Collapse Property holdings

Ownership structure Collapse Ownership structure

Corporate shareholders Collapse Corporate shareholders

Business report analysis Collapse Business report analysis

사업 개요

주요 매출원

원가 구조 / 비용 특성

자회사

차입 구조

Articles of incorporation analysis Collapse Articles of incorporation analysis

주주친화

주주비친화

기타 주목 조항

Board of directors

Auditors

Shareholder meetings and dividends

Third-party allotment limit by board resolution alone

Compensation basis

Executive compensation Collapse Executive compensation

Controlling shareholders Collapse Controlling shareholders

Holders of 5% or more Collapse Holders of 5% or more

Auditors Collapse Auditors

Executives Collapse Executives

DART disclosures Collapse DART disclosures

Activism & governance Collapse Activism & governance

광동제약의 저PBR과 자사주 처분·기업가치 제고 계획

Meeting voting results

Financial indicators

Share price history

Shareholder distribution

Annual earnings Trend

Financial statements

Property holdings

Ownership structure

Corporate shareholders

Business report analysis

Articles of incorporation analysis

Executive compensation

Controlling shareholders

Holders of 5% or more

Auditors

Executives

DART disclosures

Activism & governance